OneSource, Xbrane Partner for Global Biosimilar Supply

13 Jun 2025 CW Team

Xbrane’s biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci—a biosimilar of ranibizumab—has already received market authorisation in Europe and was launched in 2023. The product is currently under regulatory review for entry into the United States market.

Under the agreement, Xbrane will transfer the technology for selected biosimilars to OneSource’s state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility located in Bangalore, India. This move is aimed at bolstering Xbrane’s global supply chain and enhancing the regulatory readiness of OneSource’s biologics infrastructure. It is expected to accelerate approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

As part of the collaboration, OneSource has also taken part in Xbrane’s most recent funding round, underlining the long-term strategic alignment between the two firms.

Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, commented, “The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane’s proven success in biosimilar development, combined with OneSource’s fully integrated biologics platform, creates a strong foundation for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world’s leading biotech companies.”

Martin Åmark, CEO of Xbrane Biopharma, added, “Our partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.”

The collaboration is expected to enhance the reach of affordable biosimilar therapies globally, while also positioning OneSource as a leading biologics CDMO with strong regulatory and manufacturing capabilities.

OneSource Specialty Pharma Limited, a multi-modality specialty pharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic manufacturing partnership with Sweden-based Xbrane Biopharma AB (Nasdaq: XBRANE), a leading biotechnology firm. The collaboration will focus on the commercial production of Xbrane’s biosimilar portfolio.Xbrane’s biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci—a biosimilar of ranibizumab—has already received market authorisation in Europe and was launched in 2023. The product is currently under regulatory review for entry into the United States market.Under the agreement, Xbrane will transfer the technology for selected biosimilars to OneSource’s state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility located in Bangalore, India. This move is aimed at bolstering Xbrane’s global supply chain and enhancing the regulatory readiness of OneSource’s biologics infrastructure. It is expected to accelerate approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).As part of the collaboration, OneSource has also taken part in Xbrane’s most recent funding round, underlining the long-term strategic alignment between the two firms.Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, commented, “The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane’s proven success in biosimilar development, combined with OneSource’s fully integrated biologics platform, creates a strong foundation for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world’s leading biotech companies.”Martin Åmark, CEO of Xbrane Biopharma, added, “Our partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.”The collaboration is expected to enhance the reach of affordable biosimilar therapies globally, while also positioning OneSource as a leading biologics CDMO with strong regulatory and manufacturing capabilities.

Infrastructure Transport

06 May 2026

Pune To Build Nine Km Link Road Between Highways

The Pune Municipal Corporation (PMC) has decided to appoint an expert to plan the development of a nine km long, 60 metre wide road from Khadi Machine chowk to Wadki chowk as an extension to the Katraj-Kondhwa road to link the Mumbai-Satara and Pune-Solapur national highways. The scheme is intended to divert heavy vehicle traffic away from the city and improve access between the two arterial routes. The project has been prioritised by the PMC and forms part of a larger set of schemes in which 19 roads have been identified for development at a combined cost of Rs 9.82 billion (bn) to address c..

Infrastructure Transport

06 May 2026

Barabanki Bahraich Six Lane Highway Approved in Uttar Pradesh

The Uttar Pradesh government has approved construction of a new six-lane highway linking Barabanki and Bahraich as part of National Highway 927, and the cabinet has cleared the project. The alignment will pass through Mustafabad and Kaiserganj and extend for about 101.5 km, creating a key corridor for local and long-distance movement. The National Highways Authority of India will oversee the work and has signalled the scheme is intended to strengthen regional connectivity and cross-border access to Nepal. The project carries an estimated total cost of Rs 69,690 million, equivalent to Rs 69.69..

Infrastructure Transport

06 May 2026

Toll At Kharegaon Likely As Highway Upgrade Nears Completion

A section of the highway at Kharegaon has undergone an upgrade and is approaching completion, and authorities have indicated plans for a toll to be introduced once works finish. The project has focused on strengthening the carriageway, improving drainage and upgrading intersections to enhance safety and capacity. Officials have said the toll will be used to recover construction costs and fund ongoing maintenance. The upgrade included resurfacing of the pavement, widening of certain stretches and installation of modern signage and lighting to reduce accident risk. Contractors completed most ma..